Cellular Plasticity and Disease news

<p>Manuel Serrano leads the Cellular Plasticity and Disease group at IRB Barcelona</p>
5 Oct 2018

“Futuro a fondo” has published an article about the video "Meet Our Scientists", starring Manuel Serrano, a researcher at IRB Barcelona. In the video he talks about his research into how damaged tissues are repaired and therapies based on regenerative medicine.

Link to Futuro a fondo

<p>The AECC ceremony was held in Madrid yesterday, 25th September, the World Cancer Research Day</p>
25 Sep 2018

The projects address breast, lung, colon, prostate and melanoma cancer.

<p>Manuel Serrano, head of the Cellular Plasticity and Disease laboratory at IRB Barcelona</p>
3 Sep 2018

Manuel Serrano, ICREA researcher at IRB Barcelona, is the subject of the next video in the Meet Our Scientists series: “Killing zombie cells”.

In the video, Serrano talks about the work undertaken in his lab to find compounds that can remove damaged cells from the body.

<p>Miguel Rovira, researcher at IRB Barcelona</p>
30 Jul 2018

TV3's "Telenotícies" programme interviewed Miguel Rovira, a PhD student at IRB Barcelona and the first author of a recent study published in the journal EMBO Molecular Medicine. In this study, the scientists designed a nano-carrier to release drugs into damaged cells.

Link to TV3

Link to TV3 (vídeo)


<p>Manuel Serrano, group leader of the Cellular Plasticity and Disease laboratory at IRB Barcelona.</p>
27 Jul 2018

El Punt Avui, Al Día, Noticias de la Ciencia, Catalunya Press, among other media, have published an article about a study led by Manuel Serrano, leader of the Laboratory of Cellular Plasticity and Disease at IRB Barcelona, which establishes therapeutic opportunities to eliminate senescent cells in diseases such as cancer.

Link to El Punt Avui

Link to Al Día

Link to...

<p>The figure shows two views, frontal and lateral, of the image obtained by CT of the lungs of a mouse with fibrosis (grey areas) before and after receiving nano-therapy directed at senescent cells. (Guillem Garaulet and Francisca Mulero, CNIO)</p>
26 Jul 2018

A team headed by Manuel Serrano at IRB Barcelona has designed a drug encapsulation system that selectively targets senescent cells.

The study paves the way for therapeutic approaches to eliminate senescent cells in many diseases, such as pulmonary fibrosis and cancer.

<p>Image: BIST</p>
27 Jun 2018

BIST Director General says modernising research facilities and providing training to boost the social impact of science are the top priorities of the Barcelona Institute of Science and Technology

Barry C. Barish presents theory and technology behind measuring gravitational waves developed at LIGO, for which he won the 2017 Nobel Prize in Physics 

<p>Manuel Serrano, head of the Cellular Plasticity and Disease laboratory at IRB Barcelona</p>
25 Jun 2018

TV3’s "30 Minuts" has devoted a programme to whether it will be possible to extend life beyond the current limits, by slowing down or stopping aging as if it were a disease. For this documentary, they interviewed Manuel Serrano, ICREA researcher at IRB Barcelona, who comments on the process of senescence and zombie cells: "For example, if you smoke, the aging process accelerates and these zombie cells accumulate".

Link to TV3

<p>Image: BIST</p>
20 Jun 2018

Barry Barish, 2017 Nobel laureate in Physics, will speak about the ‘new science’ arising from the proof found in 1915 for the gravitational waves Einstein predicted.

The scientific re-evolution based on the new power paradigm, the latest advances in biosensors and in vitro production of specialised cells and human organs are the topics of the three debate panels.

<p>Image: El País</p>
15 Jun 2018

The newspaper El País has published an article about the implications of applying the CRISPR-Cas9 technique in human cells that could facilitate the appearance of tumours, according to two articles published in the journal Nature Medicine. The journalist interviewed Manuel Serrano, head of the Cellular Plasticity and Disease Lab at IRB Barcelona, who does not consider that these results are completely pessimistic because "Once a genetic defect has been corrected, it can be verified if these cells maintain p53, so we will have to add another quality test to use the cells that maintain it and not the others ".

Link to...